Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system

European Journal of Dermatology

Volumn 19, Issue 5, 2009, Pages 494-499

  Greiner, Roger Axel ^a   Braathen, Lasse R ^b  

^a Inselspital ^*  (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Biologics; Cost effectiveness; Moderate to severe psoriasis; Psoriasis area severity index; Responder analysis; Switzerland

Indexed keywords

ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; PLACEBO;

APPENDICITIS; ARTHRITIS; ARTICLE; ASEPTIC MENINGITIS; ASPETIC MENINGITIS; BONE INFECTION; BRONCHIOLITIS OBLITERANS; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; GASTROENTERITIS; HEALTH CARE SYSTEM; HEMATOLOGIC DISEASE; HEPATITIS; HERPES ZOSTER; HUMAN; INFECTION COMPLICATION; INFECTIOUS ARTHRITIS; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; LOWER RESPIRATORY TRACT INFECTION; LUNG TUBERCULOSIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NEIPLASIA; NEOPLASM; PERITONITIS; PNEUMONIA; PSORIASIS; SEPSIS; SIALEDENITIS; SKIN INFECTION; SOFT TISSUE INFECTION; SWITZERLAND; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HUMANS; PSORIASIS; SWITZERLAND;

EID: 69849092173     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2009.0725     Document Type: Article

References (32)

1. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006; 33: 1447-1451 (Pubitemid 44025168)
2. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320
3. Rapp SR, Feldman SR, Exum ML, Fleischer Jr. AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407
4. Spezialitaetenliste 2006: http://www.bag.admin.ch/themen/ krankenversicherung/00263/00264/00265/index.html?lang=de.
5. Patel T, Gordon KB. Adalimumab: efficacy and safety in psoriasis and rheumatic arthritis. Dermatol Ther 2004; 17: 427-431 (Pubitemid 39390596)
6. Swiss Federal Statistical Office 2007: Swiss Health Survey 2002.
7. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005; 34: 819-836
8. Leonardi CL, Toth D, Cather JC, et al. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology 2006; 213: 204-214 (Pubitemid 44567830)
9. Goffe B, Papp K, Gratton D, et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005; 27: 1912-1921 (Pubitemid 43293213)
10. Langley RG, Carey WP, Rafal ES, et al. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 2005; 27: 1317-1328
11. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-2376 (Pubitemid 44204996)
12. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004; 27: 307-324 (Pubitemid 38530461)
13. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006; 5: 197-209. (Pubitemid 43379619)
14. TARMED Suisse: www.tarmedsuisse.ch.
15. APDRG Schweiz. Kostengewichte Version 4.1. http://www.zmt.ch/de/ stationaere-tarife-apdrg-costweights-v41-deu.xls.
16. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244 (Pubitemid 8387357)
17. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005; 210: 194-199 (Pubitemid 40529233)
18. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of Etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312 (Pubitemid 40933433)
19. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001; 357: 1842-1847 (Pubitemid 32539117)
20. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606. (Pubitemid 44436647)
21. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, doubleblind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542 (Pubitemid 39278071)
22. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.e1-31.e15. (Pubitemid 44969297)
23. Reich K, Nestle FO, et al. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374
24. Arzneimittel-Kompendium Schweiz: www.kompendium.ch.
25. Analysenliste 2006, Bundesamt für Gesundheit, Bern http:// www.bag.admin.ch/themen/krankenversicherung/02874/index. html?lang=de.
26. Weiss SC, Rehmus W, Kimball AB. An assessment of the costutility of therapy for psoriasis. Ther Clin Risk Manag 2006; 2: 325-328
27. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115 (Pubitemid 350298146)
28. Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008 [Epub ahead of print].
29. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008 [Epub ahead of print].
30. Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke WH. Cost-effectiveness of psoriasis therapy with etanercept in Germany. J Dtsch Dermatol Ges 2007; 5: 762-768 (Pubitemid 47382958)
31. Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges 2007; 7: 566-574
32. Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 2008 [Epub ahead of print].